1. Home
  2. TTRX vs DBI Comparison

TTRX vs DBI Comparison

Compare TTRX & DBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Turn Therapeutics Inc.

TTRX

Turn Therapeutics Inc.

HOLD

Current Price

$16.25

Market Cap

298.8M

Sector

Health Care

ML Signal

HOLD

Logo Designer Brands Inc.

DBI

Designer Brands Inc.

HOLD

Current Price

$6.00

Market Cap

292.0M

ML Signal

HOLD

Company Overview

Basic Information
Metric
TTRX
DBI
Founded
2015
1991
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Clothing/Shoe/Accessory Stores
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
298.8M
292.0M
IPO Year
2025
2005

Fundamental Metrics

Financial Performance
Metric
TTRX
DBI
Price
$16.25
$6.00
Analyst Decision
Strong Buy
Hold
Analyst Count
1
2
Target Price
$8.00
$6.75
AVG Volume (30 Days)
91.4K
657.3K
Earning Date
05-31-2026
06-09-2026
Dividend Yield
N/A
2.73%
EPS Growth
N/A
15.00
EPS
N/A
0.34
Revenue
N/A
$2,892,671,000.00
Revenue This Year
N/A
$1.29
Revenue Next Year
N/A
$1.88
P/E Ratio
N/A
$17.88
Revenue Growth
N/A
N/A
52 Week Low
$2.57
$3.11
52 Week High
$14.50
$9.17

Technical Indicators

Market Signals
Indicator
TTRX
DBI
Relative Strength Index (RSI) 75.45 54.03
Support Level $3.49 $5.96
Resistance Level N/A $6.11
Average True Range (ATR) 1.31 0.36
MACD 0.32 0.09
Stochastic Oscillator 88.29 61.54

Price Performance

Historical Comparison
TTRX
DBI

About TTRX Turn Therapeutics Inc.

Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.

About DBI Designer Brands Inc.

Designer Brands Inc is a designer, producer, and retailer of footwear and accessories. The company operates in two reportable segments: the Retail segment and the Brand Portfolio segment. The Retail segment, which derives key revenue, operates the DSW Designer Shoe Warehouse ("DSW") banner through its direct-to-consumer stores and e-commerce sites in the United States ("U.S.") and Canada, and the Shoe Co. and Rubino banners through its direct-to-consumer stores and e-commerce sites in Canada. The Brand Portfolio segment principally earns revenue from the wholesale of its exclusive and licensed brands to retailers, its Retail segment, and international distributors, and the sale of its Vince Camuto, Keds, and Topo brands through direct-to-consumer e-commerce sites.

Share on Social Networks: